News

New data confirm that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement demonstrates key clinical benefits compared to dual antiplatelet therapy (DAPT). The findings support a streamlined antithrombotic strategy that may reduce bleeding complications while maintaining efficacy.

Digest: This evidence could influence anticoagulation management protocols post-TAVR, potentially reducing bleeding risk and healthcare costs while simplifying patient management for the growing TAVR population.